ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
9.21
9.12
(9,604.95%)
9.3008
0.0908
(0.99%)

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
9.21
Bid
-
Ask
-
Volume
87,170
8.50 Day's Range 10.38
0.0633 52 Week Range 10.40
Market Cap
Previous Close
0.0949
Open
9.13
Last Trade
500
@
9.21
Last Trade Time
Financial Volume
$ 823,132
VWAP
9.4428
Average Volume (3m)
69,474
Shares Outstanding
764,239
Dividend Yield
-
PE Ratio
-0.41
Earnings Per Share (EPS)
-22.66
Revenue
170k
Net Profit
-17.32M

About AIM ImmunoTech Inc

AIM ImmunoTech Inc. an immuno-pharma company headquartered in Ocala Florida is focused on the research and development of therapeutics to treat multiple types of cancers as well as immune-deficiency disorders. We have established a strong foundation of laboratory pre-clinical and clinical data with ... AIM ImmunoTech Inc. an immuno-pharma company headquartered in Ocala Florida is focused on the research and development of therapeutics to treat multiple types of cancers as well as immune-deficiency disorders. We have established a strong foundation of laboratory pre-clinical and clinical data with respect to the development of nucleic acids and natural interferon to enhance the natural antiviral defense system of the human body and to aid the development of therapeutic products for the treatment of certain cancers and chronic diseases. AIM ImmunoTechs flagship products include Ampligen Rintatolimod a first-in-class drug of large macromolecular RNA ribonucleic acid molecules and Alferon N Injection Interferon Alfa-N3. Ampligen represents an RNA being developed for globally important cancers viral diseases and disorders of the immune system. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Wilmington, Delaware, USA
Founded
-
AIM ImmunoTech Inc is listed in the Biological Pds,ex Diagnstics sector of the American Stock Exchange with ticker AIM. The last closing price for AIM ImmunoTech was $0.09. Over the last year, AIM ImmunoTech shares have traded in a share price range of $ 0.0633 to $ 10.40.

AIM ImmunoTech currently has 764,239 shares outstanding. The market capitalization of AIM ImmunoTech is $72,526.28 . AIM ImmunoTech has a price to earnings ratio (PE ratio) of -0.41.

AIM Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
19.11519604.952581660.094910.40.094960288.3CS
49.11519604.952581660.094910.40.094913408.3CS
129.07966962.883435580.130410.40.0633694740.15561558CS
269.02084767.864693450.189210.40.06335482860.15985856CS
528.822261.538461540.3910.40.06334460820.20331802CS
1568.41037.037037040.8110.40.06332603610.33851277CS
2606.86291.9148936172.3510.40.06338120642.02341176CS

AIM - Frequently Asked Questions (FAQ)

What is the current AIM ImmunoTech share price?
The current share price of AIM ImmunoTech is $ 9.21
How many AIM ImmunoTech shares are in issue?
AIM ImmunoTech has 764,239 shares in issue
What is the market cap of AIM ImmunoTech?
The market capitalisation of AIM ImmunoTech is USD 72.53k
What is the 1 year trading range for AIM ImmunoTech share price?
AIM ImmunoTech has traded in the range of $ 0.0633 to $ 10.40 during the past year
What is the PE ratio of AIM ImmunoTech?
The price to earnings ratio of AIM ImmunoTech is -0.41
What is the cash to sales ratio of AIM ImmunoTech?
The cash to sales ratio of AIM ImmunoTech is 41.82
What is the reporting currency for AIM ImmunoTech?
AIM ImmunoTech reports financial results in USD
What is the latest annual turnover for AIM ImmunoTech?
The latest annual turnover of AIM ImmunoTech is USD 170k
What is the latest annual profit for AIM ImmunoTech?
The latest annual profit of AIM ImmunoTech is USD -17.32M
What is the registered address of AIM ImmunoTech?
The registered address for AIM ImmunoTech is 251 LITTLE FALLS DRIVE, NEW CASTLE, WILMINGTON, DELAWARE, 19808
What is the AIM ImmunoTech website address?
The website address for AIM ImmunoTech is www.aimimmuno.com
Which industry sector does AIM ImmunoTech operate in?
AIM ImmunoTech operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AIMAIM ImmunoTech Inc
$ 9.3008
(9,700.63%)
87.17k
MITQMoving iMage Technologies Inc
$ 0.82
(48.26%)
190.7M
SYNXSilynxcom Ltd
$ 2.07
(21.76%)
818.13k
GNSGenius Group Limited
$ 0.5408
(20.71%)
66.94M
MPUMega Matrix Inc
$ 1.07
(20.22%)
711.94k
HUSAHouston American Energy Corp
$ 14.85
(-15.14%)
2.13M
RYDERyde Group Ltd
$ 0.388
(-13.78%)
11.7M
MXCMexco Energy Corp
$ 11.3961
(-13.07%)
35.33k
RODEHartford Multifactor Diversified International ETF
$ 27.57
(-12.81%)
218
CVRChicago Rivet and Machine Co
$ 11.8801
(-12.00%)
3.73k
MITQMoving iMage Technologies Inc
$ 0.82
(48.26%)
190.7M
DNNDenison Mines Corp
$ 1.73
(-5.98%)
171.46M
SOXLDirexion Daily Semiconductor Bull 3X Shares
$ 21.21
(-1.85%)
137.08M
SOXSDirexion Daily Semiconductor Bear 3X Shares New
$ 9.54
(2.03%)
133.55M
SPYSPDR S&P 500
$ 594.28
(-0.53%)
94.05M

AIM Discussion

View Posts
John_Vallay John_Vallay 6 hours ago
To All The Nay Sayers that criticize on this board and all other boards I post on - I am ALWAYS proven right.

And YES, I am smarter than most people that criticize me on these boards.

The reason I am smarter is due to some very simple Investment 101 factors: (1) anytime a public company with a market cap less than $500 million has to raise capital they will have dilution and that always leads to lower stock price, (2) when a public company does not have funds invested it means the company should not be public, (3) ALL reverse mergers and SPACS have a never-ending stock price decline among a few other Investment 101 factors.

AND YES - I am always right when the top 3 Investment 101 Factors are adhered to.
AND YES - I make a very good living with my business and even more money investing in small and micro cap companies, but most of my profits are through short positions.
AND YES - I have lost money on some of my investments, but I would say 1 out of 10 investments is a loss, 9 out of 10 is a profit.
AND YES - I pay real taxes that include short term profit taxes on investments.
AND YES - I hope to pay twice as much in taxes every year until I die.

AND NO, all the naysayers that have and will continue to criticize me do not bother or upset me. I try really hard when I post on these boards to let people know about their investment and monies that they are likely to lose because of the 3 investment 101 factors.

I like to think I bring value and can save people money.
👍️0
makinezmoney makinezmoney 5 days ago
$AIM: Added 4k here at $12

Resumed trading.......... gimme $50 today


GO $AIM
👍️0
makinezmoney makinezmoney 5 days ago
$AIM: Halt city going on here............ RS'ed 100:1

And now trading...... $11.94 here on the halt

AIM ImmunoTech Resumes Trading on NYSE Americanhttps://t.co/QsPRSH3tS1 $AIM $AIMI pic.twitter.com/csYYHMo7UQ— AIM ImmunoTech (@AimImmuno) June 17, 2025

This has that moony potential after what happens with big RS's

https://finviz.com/news/82228/aim-immunotech-resumes-trading-on-nyse-american







GO $AIM
👍️0
Renee Renee 5 days ago
AIMI changed back to AIM. Moved to the AMEX from the OTC:

https://otce.finra.org/otce/dailyList?viewType=Deletions
👍️0
Renee Renee 2 weeks ago
AIMI one for 100 reverse split:

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes
👍️0
Renee Renee 3 months ago
AIM changed to AIMI. Delisted from the AMEX to the OTC:

https://otce.finra.org/otce/dailyList?viewType=Additions
👍️0
BuckBuckBuck BuckBuckBuck 3 months ago
This thing is floating belly UP.
👍️0
lemonhead1de lemonhead1de 4 months ago
so,some interesting PR's lately...what is your personal opinion, hope etc. how this will play out in the end for us shareholders?
I know, no one knows, but yeah...what's is your feeling???

2 weeks ago, the PR that they will not proceed with the offering for now, already left many questions...

and then yesterdays double PR about the new director and his contract only for a few month till year end???somehow strange imo...

and the NYCE acceptance for listing compliance...!Top...

so yeah-what could, should, will be next???

A RS(hopefully not) or merger ,buyout etc.?

getting interesting in here:)
👍️0
81vette 81vette 4 months ago
3m buys/2m sells/174k In between,big loading and few t trades,this could pop 100% easily
👍️0
81vette 81vette 4 months ago
News,no offering until eoy filing(could be Fri)
Zero borrow,ppl saying big news coming,hype might run it up,I only have 10k in it as lotto play
👍️0
IronBard871 IronBard871 7 months ago
They're steadily sliding down, but it might still make sense to monitor the situation for a while. Equels Thomas has made modest investments in his company’s stock this year—here’s the insider trading stats for reference: https://prismo.pro/stock/aim. Regardless, shares are purchased with the aim of yielding profit. Could it be they’re preparing for one of their drugs to finally hit the mark?
👍️0
Prominent Capital Prominent Capital 9 months ago
News is out
👍️0
Prominent Capital Prominent Capital 10 months ago
Guys what is the potential on this company?
👍️0
mick mick 10 months ago
AIM
AIM ImmunoTech Inc
0.265
-0.0508 (-16.09%)
Volume: 527,731
Day Range: 0.261 - 0.3223
Last Trade Time: 12:49:35 PM EDT
Total Trades: 888
👍️0
Monksdream Monksdream 10 months ago
AIM new 52 week low
👍️0
Monksdream Monksdream 1 year ago
AIM new 52 week low
👍️0
mick mick 1 year ago
https://www.otcmarkets.com/stock/AIM
👍️0
mick mick 2 years ago
https://www.otcmarkets.com/stock/AIM
👍️0
mick mick 2 years ago
https://www.otcmarkets.com/stock/AIM
👍️0
mick mick 2 years ago
https://www.otcmarkets.com/stock/AIM
👍️0
mick mick 2 years ago
https://otcbb.swingtradebot.com/equities/AIM
👍️0
mick mick 2 years ago
AIM
AIM ImmunoTech Inc
0.67
0.052 (8.41%)
Volume: 150,500
Day Range: 0.607 - 0.68
Last Trade Time: 8:00:00 PM EDT
👍️0
mick mick 2 years ago
AIM
AIM ImmunoTech Inc
0.488
-0.032 (-6.15%)
Volume: 176,585
Day Range: 0.48 - 0.5387
Last Trade Time: 8:00:00 PM EDT
👍️0
mick mick 2 years ago
AIM
AIM ImmunoTech Inc
0.4784
0.00 (0.00%)
Volume: 61,433
Day Range: 0.475 - 0.50
Last Trade Time: 8:00:00 PM EDT
👍️0
mick mick 2 years ago
https://www.otcmarkets.com/stock/AIM
👍️0
mick mick 2 years ago
AIM
AIM ImmunoTech Inc
0.5063
0.0263 (5.48%)
Volume: 62,250
Day Range: 0.47 - 0.49
Last Trade Time: 8:00:00 PM EDT
👍️0
mick mick 2 years ago
AIM
AIM ImmunoTech Inc
0.47
0.029 (6.58%)
Volume: 26,623
Day Range: 0.4301 - 0.4586
Last Trade Time: 8:00:00 PM EDT
👍️0
mick mick 2 years ago
AIM
AIM ImmunoTech Inc
0.53
0.035 (7.07%)
Volume: 292,608
Day Range: 0.4916 - 0.55
Last Trade Time: 8:00:00 PM EST
👍️0
mick mick 2 years ago
AIM
AIM ImmunoTech Inc
0.60
0.06 (11.11%)
Volume: 98,976
Day Range: 0.5301 - 0.5779
Last Trade Time: 8:00:00 PM EST
👍️0
mick mick 2 years ago
AIM
AIM ImmunoTech Inc
0.60
0.06 (11.11%)
Volume: 98,976
Day Range: 0.5301 - 0.5779
Last Trade Time: 8:00:00 PM EST
👍️0
lowfloatwayne lowfloatwayne 2 years ago
They have one fda approved drug patent has expired and Ampligen has been denied by fda. This is a good one one to get in after the rs and wait for the bottom. Just like Maple oil
👍️ 1
Sesh Sesh 2 years ago
This company looks like they have some good potential. I recently watched a doctor from Canada who is convinced by her teams studies that the Covid vaccines cause damage to TLRs 3,7, and 8 causing people to be more susceptible to illness. Their TLR 3 nasal spray might be extremely helpful in this case.
👍️0
mick mick 3 years ago
AIM
AIM ImmunoTech Inc
0.34
-0.0067 (-1.93%)
Volume: 196,446
Day Range: 0.322 - 0.35
Last Trade Time: 8:00:00 PM EST
👍️0
mick mick 3 years ago
AIM
AIM ImmunoTech Inc
0.6286
0.0708 (12.69%)
Volume: 176,005
Day Range: 0.5678 - 0.5797
Last Trade Time: 8:00:00 PM EDT
Total Trades: 323
AIM Detailed Quote
👍️0
mick mick 3 years ago
AIM
Aerosonic Common Stock ($0.40 Par Value)
3.19
0.00 (0.00%)
Volume: -
AIM Detailed Quote
👍️0
BooDog BooDog 3 years ago
This is the AIM I see...

AIM
Bid: 0.70 Ask: 0.7089 Last: 0.7001 Chg ($): -0.0025 Vol: 20.03K
https://finviz.com/quote.ashx?t=AIM
👍️0
mick mick 3 years ago
dis is good stuff Phase 2 Study of Ampligen®
👍️0
mick mick 3 years ago
Aug-18-22 09:05AM
AIM ImmunoTech Announces Commencement of Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer
GlobeNewswire
Aug-16-22 04:05PM
AIM Stockholder Full Value Committee Reiterates Intent to Proceed with Nominations and Proxy Solicitation
GlobeNewswire
-5.50%
Aug-15-22 04:05PM
AIM ImmunoTech Provides Update on Jorgl Activist Group Litigation
Business Wire
08:05AM
AIM ImmunoTech Reports Second Quarter 2022 Financial Results and Provides Corporate Update
GlobeNewswire
👍️0
mick mick 3 years ago
AIM
Aerosonic Common Stock ($0.40 Par Value)
3.19
0.00 (0.00%)
Volume: -
AIM Detailed Quote
👍️0
mick mick 3 years ago
lot in pipeline too

Haven't even really started my DD and the first thing that caught my eye was drama!


Quote:
“The actions of AIM are a desperate attempt and part of a troubling pattern of
AIM CEO Tom Equels and directors William Mitchell and Stewart Appelrouth

wasting corporate assets at the expense of stockholders to do whatever it takes
to ensure that they run unopposed, including crafting up ‘conspiracy theories’ in

their effort to retain control and enrich themselves and deny stockholders basic rights to nominate alternative directors,
solely to keep their gravy-train of excessive compensation going,
” stated Mr. Jorgl. “

We are very pleased that the court has set the earliest date possible for expedited proceedings on our matter, which we expect will result in our nominations being allowed.”

https://finance.yahoo.com/news/aim-stockholder-full-value-committee-200500232.html


This could get interesting. Going to do some digging and put this on radar.
👍️0
BooDog BooDog 3 years ago
Just stumbled on this one Mick.

Haven't even really started my DD and the first thing that caught my eye was drama!

“The actions of AIM are a desperate attempt and part of a troubling pattern of AIM CEO Tom Equels and directors William Mitchell and Stewart Appelrouth wasting corporate assets at the expense of stockholders to do whatever it takes to ensure that they run unopposed, including crafting up ‘conspiracy theories’ in their effort to retain control and enrich themselves and deny stockholders basic rights to nominate alternative directors, solely to keep their gravy-train of excessive compensation going,” stated Mr. Jorgl. “We are very pleased that the court has set the earliest date possible for expedited proceedings on our matter, which we expect will result in our nominations being allowed.”
https://finance.yahoo.com/news/aim-stockholder-full-value-committee-200500232.html


This could get interesting. Going to do some digging and put this on radar.
👍️0
mick mick 3 years ago
AIM ImmunoTech to Present at the Virtual Investor Innovations in Oncology Spotlight Series • GlobeNewswire Inc. • 07/14/2022 12:05:00 PM
Securities Registration: Employee Benefit Plan (s-8) • Edgar (US Regulatory) • 07/01/2022 08:32:31 PM
AIM ImmunoTech Secures New State-of-the-Art Facility for Product Development and Testing • GlobeNewswire Inc. • 06/21/2022 12:35:00 PM
👍️0
mick mick 3 years ago
AIM
Aerosonic Common Stock ($0.40 Par Value)
3.19
0.00 (0.00%)
Volume: -
AIM Detailed Quote
👍️0
carldfw carldfw 3 years ago
Stop loss done pumpit Friday.
👍️0
carldfw carldfw 3 years ago
Stop loss done pumpit Friday.
👍️0
mick mick 3 years ago
AIM ImmunoTech Inc (AIM)
0.94 ? 0.02 (2.17%)
Volume: 49,334 @06/03/22 8:00:00 PM EDT
Bid Ask Day's Range
- - 0.91 - 0.93
AIM Detailed Quote
👍️0
mick mick 3 years ago
AIM ImmunoTech Inc (AIM)
1.06 ? 0.01 (0.95%)
Volume: 115,978 @04/29/22 8:00:00 PM EDT
Bid Ask Day's Range
- - 1.03 - 1.08
AIM Detailed Quote
👍️0
crudeoil24 crudeoil24 3 years ago
AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today provided a summary of clinical data that support the synergistic potential of Ampligen® (rintatolimod) with checkpoint blockade therapies.
Thomas Equels, Chief Executive Officer of AIM, commented, “We have amassed a growing body of encouraging Ampligen data to date through close collaborations with leading KOLs at preeminent institutions. These data have not only affirmed but significantly evolved our belief that Ampligen as a single agent therapy, as well as in combination with the latest powerful cancer therapies, has the potential to become a breakthrough therapy for some of the most difficult to treat and deadly cancers. We are going to continue working tirelessly to advance Ampligen towards approval and commercialization with the goal of bringing much needed hope to patients and solutions to treating physicians around the world.”

Ampligen is the Company’s dsRNA drug currently being developed for globally important cancers. Ampligen has shown therapeutic synergy with checkpoint inhibitors, including increasing survival rates and efficacy, in the treatment of animal tumors when used in combination with checkpoint blockade therapies. The first detection of Ampligen’s synergistic potential with checkpoint blockade therapeutics was witnessed in pre-clinical mouse models of melanoma and pancreatic cancers. Additionally, the Company now has data from two clinical studies — in advanced recurrent ovarian cancer and triple negative breast cancer — that indicate that the drug may have similar anti-tumor activity in humans.

“Working with AIM, our Pancreatic Cancer R&D team at the Buffett Cancer Center did extensive pre-clinical research demonstrating in animal models that Ampligen had a significant therapeutic benefit in treating pancreatic cancer. This March, Prof. C.H.J. van Eijck and his team at Erasmus MC published data in the journal Cancers showing Ampligen alone was associated with extended overall survival in late-stage pancreatic cancer of 19 months. Just last week, at AACR, publications of clinical data by UPMC’s Dr. Bob Edwards in advanced recurrent ovarian cancer, and Roswell’s Dr. Pawel Kalinski in both stage 4 triple negative breast cancer and stage 4 colorectal cancer, strongly supported the advance of Ampligen into human trials for patients in pancreatic and other cancers where checkpoint drugs are not effective,” stated Michael (Tony) Hollingsworth, PhD, Associate Director, Basic Research, University of Nebraska Medical Center.

“Checkpoint drugs are powerful and important therapies, but only work on ‘hot’ tumors visible to the immune system, not ‘cold’ tumors that are immune-silent. Ampligen appears, from these data, to turn cold tumors into hot tumors and create significant therapeutic potential for a successful second round of Ampligen plus checkpoint therapy for those who do not respond to checkpoint therapy alone,” added Robert Edwards, MD, University of Pittsburgh School of Medicine and University of Pittsburgh Cancer Institute.

“The two ongoing Roswell Park clinical trials we recently presented findings from represent milestones in our 10-year-long NIH and DoD-funded research program aiming to convert immuno-resistant ‘cold’ tumors into ‘hot’ ones that would be more sensitive to immunotherapy. Seeing both studies successfully meet their predetermined efficacy endpoint — selective increase of cytotoxic T lymphocyte markers in tumor tissues — Roswell Park plans to move forward with critical studies assessing therapeutic efficacy of the combination of a rintatolimod-based chemokine-modulating regimen with PD-1 inhibitors, cancer vaccines and/or adoptive T cell therapies in solid tumors. Observations from our preclinical studies suggest that this multipronged strategy may benefit patients with multiple solid-tumor lesions, which are difficult to target individually,” commented Pawel Kalinski, MD, PhD, Jacobs Family Endowed Chair of Immunology, Chief of the Division of Translational Immuno-Oncology and Senior Vice President for Team Science at, Roswell Park Comprehensive Cancer Center.

Recurrent Ovarian Cancer: ClinicalTrials.gov: NCT03734692

The investigator-initiated, Phase 2, single-arm, efficacy/safety trial to evaluate the effectiveness of combining intensive locoregional intraperitoneal (IP) chemoimmunotherapy of cisplatin with IP Ampligen (TLR-3 agonist) and IV infusion of the checkpoint inhibitor pembrolizumab (KEYTRUDA®) (IVP) for patients with recurrent platinum-sensitive ovarian cancer is being conducted by the University of Pittsburgh Medical Center (UPMC). The Phase 2 trial is designed to enroll up to 45 subjects using Ampligen in combination with pembrolizumab to test the combinational activity of checkpoint blockade therapy where Ampligen is administered by injection in the peritoneal cavity where the tumor is located.

The Company’s recently announced positive interim results suggesting induction of T cell activation together with clinical responses may indicate prognostic evidence of tumor environment reprogramming that we do not see with chemotherapy alone and which may extend survival. A total of 17 patients have been enrolled and 13 were evaluable for response in the ongoing Phase 2 trial. The observed clinical responses were: 2 complete responses (15.4%), 3 partial responses (23.1%), 3 stable disease (23.1%), 5 progressions (38.4%) for a clinical benefit rate (CR+PR+SD) of 61.6%. From 13 patients, 77 IP wash samples were collected at serial time points. Measurements in IP washes revealed an acute increase in granzyme B (GZMB), perforin, TNF alpha, CXCL9, CXCL10 and CXCL11 after treatment (p<0.05). Longitudinal data revealed a progressive increase in some biomarkers in the locoregional environment; CXCL9, CXCL10, CXCL11, perforin and TNF alpha were all increased from baseline levels at cycle 1 to baseline of cycle 6 (p<0.05). CXCL12 was also increased acutely after treatment (p<0.05).

The cytokine CXCL12 observed to increase acutely after treatment functions as a chemotactic for lymphocytes. The cytokines CXCL9-11 active in antitumor responses in modulation of the tumor microenvironment (TME) to favor cytotoxic T cells required for anti-tumor cell immune activity versus regulatory T cells (Tregs), which function to protect non-tumor “self” tissue. Granzymes are serine proteases released by cytoplasmic granules within cytotoxic T cells and natural killer (NK) cells. They induce programmed cell death (apoptosis) in the target cell, eliminating cells that have become cancerous. Perforin is a protein, which creates tubules in the cell membrane allowing cell lysis. Perforin is a key effector molecule for T-cell- and natural killer-cell-mediated cytolysis.
👍️0
mick mick 3 years ago
https://www.otcmarkets.com/stock/AIM
👍️0
mick mick 3 years ago
AIM ImmunoTech Inc (AIM)
0.839899 ? -0.000001 (-0.00%)
Volume: 152,721 @03/11/22 8:00:00 PM EST
Bid Ask Day's Range
- - 0.8054 - 0.86
AIM Detailed Quote
👍️0

Your Recent History

Delayed Upgrade Clock